StockData
Disc Medicine, Inc. logo

Disc Medicine, Inc. (IRON) stock

IRONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$77.98+1.41 (+1.84%)

Close on Nov 18, 2026Market cap $2.99BP/E –Yield –

Disc Medicine operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Disc Medicine's operating income for the twelve months ending Jun 30, 2026 was -$269.27M. For fiscal 2025 it was -$236.02M. The highest annual figure on record is -$30.93M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$236.02M–
FY2024Dec 31, 2024-$129.72M–
FY2023Dec 31, 2023-$91.13M–
FY2022Dec 31, 2022-$47.48M–
FY2021Dec 31, 2021-$30.93M–
FY2020Dec 31, 2020-$34.04M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$65.08M–
Q1 FY2026Mar 31, 2026-$69.52M–
Q4 FY2025Dec 31, 2025-$66.97M–
Q3 FY2025Sep 30, 2025-$67.70M–
Q2 FY2025Jun 30, 2025-$61.41M–
Q1 FY2025Mar 31, 2025-$39.95M–
Q4 FY2024Dec 31, 2024-$34.55M–
Q3 FY2024Sep 30, 2024-$32.86M–
Q2 FY2024Jun 30, 2024-$30.85M–
Q1 FY2024Mar 31, 2024-$31.46M–
Q4 FY2023Dec 31, 2023-$29.71M–
Q3 FY2023Sep 30, 2023-$18.96M–
Q2 FY2023Jun 30, 2023-$17.33M–
Q1 FY2023Mar 31, 2023-$25.13M–
Q4 FY2022Dec 31, 2022-$15.02M-173.9%
Q3 FY2022Sep 30, 2022-$10.48M–
Q2 FY2022Jun 30, 2022-$12.02M–
Q1 FY2022Mar 31, 2022-$9.96M–
Q4 FY2021Dec 31, 2021$20.33M–
Q3 FY2021Sep 30, 2021-$18.45M–
Q2 FY2021Jun 30, 2021-$16.32M–
Q1 FY2021Mar 31, 2021-$16.49M–
Q4 FY2020Dec 31, 2020-$9.79M–
Q3 FY2020Sep 30, 2020-$7.95M–
Q2 FY2020Jun 30, 2020-$6.67M–
Q1 FY2020Mar 31, 2020-$9.63M–

More Disc Medicine figures

See a number that looks wrong?